Melanoma Matters22 Joulu 2025

Ep 74: Best of ESMO 2025: Part 2 of 2

Summary

In this Part 2 Best of ESMO 2025 episode of Melanoma Matters, hosts James Larkin and Sapna Patel cover the IO Biotech phase 3 trial, Checkmate 238 final results, the Safe Stop trial, the ECOG-ACRIN STAMP trial for Merkel cell carcinoma, and a promising TCR therapy for uveal melanoma.

Keywords

melanoma, cancer research, immunotherapy, clinical trials, ESMO, IO Biotech, Checkmate 238, Safe Stop trial, STAMP trial, uveal melanoma

Takeaways

The IO Biotech trial missed its primary endpoint for PFS.

Checkmate 238 confirmed previous findings on RFS and DMFS.

The Safe Stop trial suggests early discontinuation of therapy may be safe.

STAMP trial shows potential for adjuvant pembrolizumab in Merkel cell carcinoma.

Uveal melanoma TCR therapy shows promise.

Understanding subgroup analysis in interpreting trial results.

Patient management decisions should consider trial limitations and real-world implications.

Chapters

00:00 Travel Tips and Strategies

04:43 IO Biotech Phase 3 Trial Insights

12:00 Checkmate 238 Discussion

13:10 Navigating Publication Challenges

13:59 Checkmate 238 Results

15:58 Late Relapses and Follow-Up Strategies

17:57 Time of Day of Infusion

20:50 Safe Stop Trial: Evaluating Treatment Duration

33:12 STAMP Trial: Adjuvant Therapy for Merkel Cell Carcinoma

35:05 IMA-203 (Anzu-cel) trial in uveal melanoma

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(87)

Ep 83: Guest Megan Othus and Time of Day Administration

James and Sapna welcome Megan Othus, Professor of Biostatistics at the Fred Hutch Cancer Center and one of the key statisticians at SWOG.Megan talks about growing up in the PNW and going East to get b...

24 Kesä 40min

Ep 82: Best of ASCO: 2026

In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications.They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, f...

13 Kesä 1h 4min

Live from ASCO 2026: a preview

James & Sapna sent a brief message from ASCO 2026 about what they are looking forward to hearing at the meeting.OptimUM-02ADAMKN-942Neoadjuvant pilot studies... and more

1 Kesä 6min

Ep 81: IGNYTE trial (RP1 + nivo)

SummaryThe conversation covers the published data from the IGNYTE study - RP1 + nivolumab: response rate and safety profile, RNA-seq analysis, and toxicity. The key takeaways include insights into cli...

13 Helmi 32min

Ep 80: 2025 Holiday Special

SummaryHappy Holidays and Festive Season Everyone! In this episode of Melanoma Matters, hosts Sapna Patel and James reflect on their "cultural" experiences over the past year, discussing movies, music...

30 Joulu 202535min

Ep 79: coBRIM, COMBI-d 5-year follow-up

SummaryIn this episode of Melanoma Matters, James awaits an invitation to a film premiere (The Penguin Lessons) and we all await a picture of him in his tuxedo! Sapna and James go on to discuss the 5-...

29 Joulu 202536min

Ep 78 TRAILER: MEK inhibitor trials

Enjoy this short trailer on MEK inhibitor monotherapy trials in melanoma

29 Joulu 20251min

Ep 78: MEK inhibitor trials (METRIC, NEMO, pimasertib)

SummarySo many shoutouts in this episode of Melanoma Matters! Sapna and James engage in a lively discussion about MEK inhibitors as monotherapy treatment. They explore the METRIC, NEMO, and pimasertib...

29 Joulu 202537min